Foundation Medicine and AstraZeneca have partnered to develop a diagnostic assay for Lynparza designed to identify patients most likely to benefit from the treatment.
A poly ADP-ribose polymerase inhibitor, AZ’s Lynparza works by exploiting tumor DNA repair pathway deficiencies to preferentially kill cancer cells.
Under the agreement, Foundation Medicine will develop the assay that will aim to detect multiple classes of genomic alterations across a range of genes involved in homologous recombination repair.
Financial terms of the deal were not disclosed. — Michael Cipriano